Public Release: 

Consensus statement from the International Radiosurgery Oncology Consortium for Kidney

Published in Future Oncology

Future Science Group

IMAGE

IMAGE: Future Science Group today announced the publication of a new article in Future Oncology, presenting a consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell... view more

Credit: Future Science Group

Future Science Group today announced the publication of a new article in Future Oncology, presenting a consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma (RCC). This consensus statement is the result of a collaborative effort from experts worldwide, and identifies key methods for the safe implementation and practice of Stereotactic Body Radiation Therapy (SBRT) for primary RCC. These guidelines may aid the standardization of treatment delivery.

SBRT is an emerging non-invasive treatment option for patients with inoperable primary RCC with favorable comparisons to already available non-invasive treatments. Expertise in this technique has been developed at several institutions worldwide, but this is the first consensus statement from the newly formed international consortium.

"Stereotactic radiotherapy is an emerging innovative therapy for patients with inoperable kidney cancer and IROCK has devised an important consensus framework for the technique", explained Shankar Siva, of the Peter MacCallum Cancer Centre (Melbourne, Australia) and lead author of the guidelines. "This work is a much-needed practical guide for patient selection and management in this developing field."

Nick Ward, Commissioning Editor for Future Oncology, added: "As noted by the authors, SBRT for primary RCC is non-invasive, well tolerated, cost-effective and widely available. This method is expected to become the standard option for inoperable primary RCC within the next decade and guidelines such as these can help facilitate multi-institutional studies to establish efficacy and survival outcomes after this treatment."

###

To read the full issue, please click here

Additional articles and cancer content can be found on Oncology Central, Future Science Group's free eCommunity for oncology professionals. The membership-based portal offers free access to breaking oncology news and peer-reviewed journal articles, with content selected by fellow clinicians.

About Future Oncology

Future Oncology is a MEDLINE-indexed journal, with an impact factor of 2.477. The journal covers the latest scientific and clinical issues, together with the economic and policy issues of relevance to oncologists. The journal delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.